Aptamer Group
plc
("Aptamer", the "Company" or
the "Group")
Director
Appointment
Aptamer Group plc (AIM: APTA), the
developer of novel Optimer® binders to enable innovation
in the life sciences industry, announces the appointment of Tim
Sykes to its Board of Directors as a Non-Executive Director with
immediate effect.
Tim is an experienced executive and
non-executive director, having been CEO and, previously, CFO of
Proactis Holdings PLC between 2006 and 2022 and having served as
fractional or transitionary CFO at Avacta Group plc, Altitude
Group, and Eleco plc. Tim currently serves as Non-Executive
Director at Data Connect Group Limited and as fractional CFO at Rio
AI Limited. Tim is a qualified chartered accountant, and at
Aptamer Group he is Chair of the Audit Committee and a member of
the Remuneration Committee.
Dr
Adam Hargreaves, Chair of the Board of Aptamer Group,
commented: "As we refocus the Group
to capitalise on the Optimer assets that have been developed, it is
important that the Aptamer Board has the right commercial,
financial and operational expertise to support this. We are excited
to welcome Tim to the Board, confident that his insights will be
invaluable in shaping our capital market strategy and enhancing the
financial management of the business."
Dr
Arron Tolley, Chief Executive Officer of Aptamer Group,
added: "With our platform
technologies gaining traction and strong performance validation
across the life sciences and healthcare sectors, we are evolving
our Board to align with the strategic needs of the company. Tim's
extensive experience in managing AIM-listed companies will be a
crucial asset as we continue to grow."
Tim
Sykes, Non-Executive Director of Aptamer Group, said:
"I'm delighted to be joining the Board of Aptamer
Group at this critical time for the Company, where the focus on
strategic Optimer assets represents a potential significant value
inflection point. I look forward to collaborating with the Board
and management team at Aptamer, leveraging my experience to
contribute to the Company's strategic direction and future
success."
Additional disclosures
regarding Mr Sykes' appointment
The following details in relation to
the appointment of Timothy James Sykes, aged 54, are disclosed in
accordance with Schedule 2(g) of the AIM Rules:
|
Current
directorships:
|
Former appointments within
the past 5 years:
|
|
Data Connect Group
Limited
Mooring Management (Filey)
Limited
|
Proactis Holdings PLC
|
In 2018, Mr Sykes was a director of
Penta Financial Direction Limited when it was liquidated with no
loss to creditors.
In 2017, Mr Sykes was a director of
Proactis Total Procure Limited, which was a Proactis joint venture
in India, when it was compulsorily struck off having ceased to
trade.
- ENDS
-
For further information, please
contact:
|
Aptamer Group plc
Arron Tolley
|
+44 (0) 1904 217
404
|
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368
3550
|
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders
through its proprietary Optimer® platform to enable new
approaches in therapeutics, diagnostics, and research applications.
The Company strives to deliver transformational solutions that meet
the needs of life science researchers and
developers.
Optimer binders are oligonucleotide
affinity ligands that can function as an antibody alternative. The
global affinity ligand market is currently worth over $170
billion.
Aptamer has successfully delivered
projects for a range of global pharma companies, diagnostic
development companies, and research institutes, covering multiple
application areas with the objective of establishing
royalty-bearing licenses.